Lion Point Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Lion Point Capital’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$691K	Hold	112,434	–	–	4.13%	8
2025 Q4	$866K	Sell	112,434 -10,566	-9%	-$86.7K	4.48%	4
2025 Q3	$1.15M	Sell	123,000 -72,700	-37%	-$629K	6.54%	3
2025 Q2	$1.62M	Hold	195,700	–	–	11.03%	1
2025 Q1	$1.19M	Hold	195,700	–	–	7.6%	4
2024 Q4	$1.24M	Sell	195,700 -19,300	-9%	-$98.9K	6.48%	5
2024 Q3	$1.07M	Buy	215,000 +45,000	+26%	+$260K	2.39%	11
2024 Q2	$1.04M	Hold	170,000	–	–	1.89%	14
2024 Q1	$1.89M	Buy	170,000 +60,000	+55%	+$602K	1.06%	10
2023 Q4	$1.23M	Hold	110,000	–	–	0.62%	13
2023 Q3	$826K	Hold	110,000	–	–	0.37%	17
2023 Q2	$971K	Buy	+110,000	New	+$915K	0.44%	18

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Lion Point Capital's FENC Position: Q1 2026 in Review

Lion Point Capital held its Fennec Pharmaceuticals (FENC) position steady in Q1 2026 at 112,434 shares worth $691K. The position accounts for 4.13% of the portfolio, ranked #8.

Lion Point Capital first reported a position in FENC in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.89M in Q1 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

Lion Point Capital held 112,434 shares of Fennec Pharmaceuticals worth $691K as of Q1 2026.
Lion Point Capital left its Fennec Pharmaceuticals share count unchanged in Q1 2026.
Fennec Pharmaceuticals made up 4.13% of Lion Point Capital's portfolio in Q1 2026, its #8 holding.
Lion Point Capital first reported a position in Fennec Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Lion Point Capital's Fennec Pharmaceuticals position peaked at $1.89M in Q1 2024.
90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.